Adozelesin

Drug Profile

Adozelesin

Alternative Names: Adosar; U 73975

Latest Information Update: 02 May 2008

Price : $50

At a glance

  • Originator Pharmacia Corporation
  • Developer Pharmacia Corporation; Yakult Honsha
  • Class Antineoplastics; Cyclohexanes; Indoles
  • Mechanism of Action Alkylating agents; DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Breast cancer; Cancer; Solid tumours

Most Recent Events

  • 05 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
  • 05 Jul 1999 A study has been added to the therapeutic trials and adverse events sections
  • 12 Dec 1998 Phase-II clinical trials for Breast cancer treatment in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top